The majority of adverse reactions were mild to moderate in severity; injection site reactions and arthralgia occurred most frequently2
In clinical trials, the rate of adverse reactions decreased over time1
The exposure-adjusted rate represents the number of episodes divided by patient-years (the number of patients multiplied by the years patients were exposed to treatment).1
Non–IgE-mediated anaphylaxis observed
in phase 3 clinical trials1
In clinical trials with an induction/titration/maintenance regimen, 9% of patients (26 of 285) experienced a total of 37 anaphylaxis episodes1
No drug-specific IgE was detected at or near the time of the episodes1†
18 of 26 (69%) patients who experienced anaphylaxis were rechallenged. 13 of 18 (72%) were able to continue therapy without experiencing recurrence, and 5 of 18 (28%) patients who were rechallenged had recurrence of anaphylaxis1
Most episodes occurred within 1 hour after injection (76%; 28 of 37 episodes), though delayed episodes also occurred up to 48 hours after administration of PALYNZIQ™ (pegvaliase-pqpz) Injection1
Most episodes occurred within the first year of dosing (78%; 29 of 37 episodes), but cases also occurred after 1 year of dosing and up to 834 days (2.3 years) of total follow-up1
Management of anaphylaxis in clinical trials1
54% of anaphylaxis episodes (20 of 37) were managed with administration of auto-injectable epinephrine
All anaphylaxis episodes resolved without sequelae1
25 of 26 patients who had anaphylaxis were tested for anti–pegvaliase-pqpz IgE antibodies, which recognize the PEGylated protein product. Of those 25 patients, 24 tested negative. The 1 patient who screened positive for anti–pegvaliase-pqpz IgE had insufficient sample to confirm IgE positivity. This patient tested negative for anti–pegvaliase-pqpz IgE at routine visits before and after the anaphylaxis episode (not at times of anaphylaxis).1
Type III immune complex–mediated hypersensitivity reactions
Since PALYNZIQ is a nonhuman enzyme, it elicits an immune response and may cause hypersensitivity reactions1
Hypersensitivity reactions, other than anaphylaxis, occurred in 69% of patients (196 of 285) treated with PALYNZIQ1
The rate of hypersensitivity reactions was highest during the induction/titration phases and decreased during the maintenance phase, but reactions can occur at any time1
Management of hypersensitivity reactions should be based on severity and recurrence of the reaction and clinical judgment of the healthcare provider, and may include treatment with antihistamines, antipyretics, and/or corticosteroids, as well as dosage adjustment, temporary drug interruption, or drug discontinuation1
Strategies for managing potential anaphylaxis episodes
Prescriber enrollment is one time only; each patient must enroll separately
Prescribe auto-injectable epinephrine to all patients treated with PALYNZIQ. Prior to the first dose, instruct the patient and adult observer (if applicable) on how to recognize the signs and symptoms of anaphylaxis, on how to properly administer auto-injectable epinephrine, and to seek immediate medical care upon its use1
Instruct patients to carry auto-injectable epinephrine with them at all times during treatment with PALYNZIQ1
Considerations
Having an adult observer for patients who may need assistance in recognizing and managing anaphylaxis or for other patients during treatment with PALYNZIQ1
If an adult observer is needed, the observer should be present during and for at least 1 hour after administration of PALYNZIQ, and should be able to administer auto-injectable epinephrine and call for emergency medical support upon its use1
Premedication with the following, based on individual patient tolerability, prior to each dose of PALYNZIQ1:
H1 antagonist
H2 antagonist
Antipyretic
References:1. PALYNZIQ [package insert]. Novato, CA: BioMarin Pharmaceutical Inc; 2018. 2. Thomas J, Levy H, Amato S, et al, for the PRISM investigators. Pegvaliase for the treatment of phenylketonuria: results of a long-term phase 3 clinical trial program (PRISM). Mol Genet Metab. 2108;124(1):27-38.
Thank you!
We'll be in touch soon with additional information.
Important Safety Information
WARNING: RISK OF ANAPHYLAXIS
BOXED WARNING: RISK OF ANAPHYLAXIS
Anaphylaxis has been reported after administration of PALYNZIQ and may occur at any time during
treatment with PALYNZIQ
Administer the initial dose of PALYNZIQ under the supervision of a healthcare provider equipped
to manage anaphylaxis, and closely observe patients for at least 60 minutes following injection. Prior to
self-injection, confirm patient competency with self-administration, and patient’s and observer’s (if
applicable) ability to recognize signs and symptoms of anaphylaxis and to administer auto-injectable
epinephrine, if needed
Prescribe auto-injectable epinephrine to all patients treated with PALYNZIQ. Prior to the first
dose, instruct the patient and observer (if applicable) on its appropriate use. Instruct the patient to
seek immediate medical care upon its use. Instruct patients to carry auto-injectable epinephrine with
them at all times during treatment with PALYNZIQ
PALYNZIQ is available only through a restricted program under a Risk Evaluation and Mitigation
Strategy (REMS) called the PALYNZIQ REMS. Further information, including a list of qualified pharmacies,
is available at www.PALYNZIQREMS.com or by
telephone at 1-855-758-REMS (1-855-758-7367)
WARNINGS AND PRECAUTIONS
Anaphylaxis
Signs and symptoms of anaphylaxis reported include syncope, hypotension, hypoxia, dyspnea, wheezing,
chest discomfort/chest tightness, tachycardia, angioedema (swelling of face, lips, eyes, tongue), throat
tightness, skin flushing, rash, urticaria, pruritus, and gastrointestinal symptoms (vomiting, nausea,
diarrhea)
Anaphylaxis generally occurred within 1 hour after injection; however, delayed episodes occurred up to 48
hours after PALYNZIQ administration
Consider having an adult observer for patients who may need assistance in recognizing and managing
anaphylaxis during treatment with PALYNZIQ. If an adult observer is needed, the observer should be present
during and for at least 60 minutes after administration of PALYNZIQ, and should be able to administer
auto-injectable epinephrine and call for emergency medical support upon its use
Anaphylaxis requires immediate treatment with auto-injectable epinephrine. Prescribe auto-injectable
epinephrine to all patients receiving PALYNZIQ and instruct patients to carry auto-injectable epinephrine
with them at all times during treatment with PALYNZIQ. Prior to the first dose, instruct the patient and
observer (if applicable) on how to recognize the signs and symptoms of anaphylaxis, on how to properly
administer auto-injectable epinephrine, and to seek immediate medical care upon its use. Consider the risks
associated with auto-injectable epinephrine use when prescribing PALYNZIQ. Refer to the auto-injectable
epinephrine Prescribing Information for complete information
Consider the risks and benefits of readministering PALYNZIQ following an episode of anaphylaxis. If the
decision is made to readminister PALYNZIQ, administer the first dose under the supervision of a healthcare
provider equipped to manage anaphylaxis and closely observe the patient for at least 60 minutes following
the dose. Subsequent dose titration of PALYNZIQ should be based on patient tolerability and therapeutic
response
Consider premedication with an H1-receptor antagonist, H2-receptor antagonist,
and/or antipyretic prior to administration of PALYNZIQ based upon individual patient tolerability
Other Hypersensitivity Reactions
Hypersensitivity reactions other than anaphylaxis have been reported in 196 of 285 (69%) patients treated
with PALYNZIQ
Consider premedication with an H1-receptor antagonist, H2-receptor antagonist,
and/or antipyretic prior to PALYNZIQ administration based upon individual patient tolerability
Management of hypersensitivity reactions should be based on the severity of the reaction, recurrence of
the reaction, and the clinical judgment of the healthcare provider, and may include dosage adjustment,
temporary drug interruption, drug discontinuation, or treatment with antihistamines, antipyretics, and/or
corticosteroids
ADVERSE REACTIONS
The most common adverse reactions (at least 20% of patients in either treatment phase) were injection
site reactions, arthralgia, hypersensitivity reactions, headache, generalized skin reaction lasting at
least 14 days, pruritus, nausea, abdominal pain, oropharyngeal pain, vomiting, cough, diarrhea, and fatigue
Of the 285 patients exposed to PALYNZIQ in an induction/titration/maintenance regimen in clinical trials,
31 (11%) patients discontinued treatment due to adverse reactions. The most common adverse reactions
leading to treatment discontinuation were hypersensitivity reactions (6% of patients)—including anaphylaxis
(3% of patients) and angioedema (1% of patients)—arthralgia (4% of patients), generalized skin reactions
lasting at least 14 days (2% of patients), and injection site reactions (1% of patients)
The most common adverse reactions leading to dosage reduction were arthralgia (14% of patients),
hypersensitivity reactions (9% of patients), injection site reactions (4% of patients), alopecia (3% of
patients), and generalized skin reactions lasting at least 14 days (2% of patients)
The most common adverse reactions leading to temporary drug interruption were arthralgia (13% of
patients), hypersensitivity reactions (13% of patients), anaphylaxis (4% of patients), and injection site
reactions (4% of patients)
Blood Phenylalanine Monitoring and Diet
Obtain blood phenylalanine concentrations every 4 weeks until a maintenance dosage is established
After a maintenance dosage is established, periodically monitor blood phenylalanine concentrations
Counsel patients to monitor dietary protein and phenylalanine intake, and adjust as directed by their
healthcare provider
DRUG INTERACTIONS
Effect of PALYNZIQ on Other PEGylated Products
In a single-dose study of PALYNZIQ in adult patients with PKU, 2 patients receiving concomitant
injections of medroxyprogesterone acetate suspension (a formulation containing PEG 3350) experienced
hypersensitivity reactions, and 1 of the 2 patients also experienced anaphylaxis
The clinical effects of concomitant treatment with different PEGylated products is unknown. Monitor
patients treated with PALYNZIQ and concomitantly with other PEGylated products for hypersensitivity
reactions
USE IN SPECIFIC POPULATIONS
Pregnancy and Lactation
PALYNZIQ may cause fetal harm when administered to a pregnant woman
If PALYNZIQ is administered during pregnancy, or if a patient becomes pregnant while receiving PALYNZIQ
or within 1 month following the last dose of PALYNZIQ, healthcare providers should report PALYNZIQ exposure
by calling 1-866-906-6100
Monitor blood phenylalanine concentrations in breastfeeding women treated with PALYNZIQ
Pediatric Use
The safety and efficacy of PALYNZIQ in pediatric patients have not been established
Geriatric Use
Clinical studies of PALYNZIQ did not include patients aged 65 years and older
You are encouraged to report suspected adverse reactions to BioMarin at 1-866-906-6100
and the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see full Prescribing Information, including Boxed Warning, at PALYNZIQ.com/hcp.
INDICATION
PALYNZIQ™ (pegvaliase-pqpz) Injection is a phenylalanine-metabolizing enzyme indicated to reduce blood
phenylalanine concentrations in adult patients with phenylketonuria (PKU) who have uncontrolled blood
phenylalanine concentrations greater than 600 µmol/L on existing management.
Important Safety Information
WARNING: RISK OF ANAPHYLAXIS
BOXED WARNING: RISK OF ANAPHYLAXIS
Anaphylaxis has been reported after administration of PALYNZIQ and may occur at any time during
treatment with PALYNZIQ
Administer the initial dose of PALYNZIQ under the supervision of a healthcare provider equipped
to manage anaphylaxis, and closely observe patients for at least 60 minutes following injection. Prior to
self-injection, confirm patient competency with self-administration, and patient’s and observer’s (if
applicable) ability to recognize signs and symptoms of anaphylaxis and to administer auto-injectable
epinephrine, if needed
Prescribe auto-injectable epinephrine to all patients treated with PALYNZIQ. Prior to the first
dose, instruct the patient and observer (if applicable) on its appropriate use. Instruct the patient to
seek immediate medical care upon its use. Instruct patients to carry auto-injectable epinephrine with
them at all times during treatment with PALYNZIQ
PALYNZIQ is available only through a restricted program under a Risk Evaluation and Mitigation
Strategy (REMS) called the PALYNZIQ REMS. Further information, including a list of qualified pharmacies,
is available at www.PALYNZIQREMS.com or by
telephone at 1-855-758-REMS (1-855-758-7367)
WARNINGS AND PRECAUTIONS
Anaphylaxis
Signs and symptoms of anaphylaxis reported include syncope, hypotension, hypoxia, dyspnea, wheezing,
chest discomfort/chest tightness, tachycardia, angioedema (swelling of face, lips, eyes, tongue), throat
tightness, skin flushing, rash, urticaria, pruritus, and gastrointestinal symptoms (vomiting, nausea,
diarrhea)
Anaphylaxis generally occurred within 1 hour after injection; however, delayed episodes occurred up to 48
hours after PALYNZIQ administration
Consider having an adult observer for patients who may need assistance in recognizing and managing
anaphylaxis during treatment with PALYNZIQ. If an adult observer is needed, the observer should be present
during and for at least 60 minutes after administration of PALYNZIQ, and should be able to administer
auto-injectable epinephrine and call for emergency medical support upon its use
Anaphylaxis requires immediate treatment with auto-injectable epinephrine. Prescribe auto-injectable
epinephrine to all patients receiving PALYNZIQ and instruct patients to carry auto-injectable epinephrine
with them at all times during treatment with PALYNZIQ. Prior to the first dose, instruct the patient and
observer (if applicable) on how to recognize the signs and symptoms of anaphylaxis, on how to properly
administer auto-injectable epinephrine, and to seek immediate medical care upon its use. Consider the risks
associated with auto-injectable epinephrine use when prescribing PALYNZIQ. Refer to the auto-injectable
epinephrine Prescribing Information for complete information
Consider the risks and benefits of readministering PALYNZIQ following an episode of anaphylaxis. If the
decision is made to readminister PALYNZIQ, administer the first dose under the supervision of a healthcare
provider equipped to manage anaphylaxis and closely observe the patient for at least 60 minutes following
the dose. Subsequent dose titration of PALYNZIQ should be based on patient tolerability and therapeutic
response
Consider premedication with an H1-receptor antagonist, H2-receptor antagonist,
and/or antipyretic prior to administration of PALYNZIQ based upon individual patient tolerability
Other Hypersensitivity Reactions
Hypersensitivity reactions other than anaphylaxis have been reported in 196 of 285 (69%) patients treated
with PALYNZIQ
Consider premedication with an H1-receptor antagonist, H2-receptor antagonist,
and/or antipyretic prior to PALYNZIQ administration based upon individual patient tolerability
Management of hypersensitivity reactions should be based on the severity of the reaction, recurrence of
the reaction, and the clinical judgment of the healthcare provider, and may include dosage adjustment,
temporary drug interruption, drug discontinuation, or treatment with antihistamines, antipyretics, and/or
corticosteroids
ADVERSE REACTIONS
The most common adverse reactions (at least 20% of patients in either treatment phase) were injection
site reactions, arthralgia, hypersensitivity reactions, headache, generalized skin reaction lasting at
least 14 days, pruritus, nausea, abdominal pain, oropharyngeal pain, vomiting, cough, diarrhea, and fatigue
Of the 285 patients exposed to PALYNZIQ in an induction/titration/maintenance regimen in clinical trials,
31 (11%) patients discontinued treatment due to adverse reactions. The most common adverse reactions
leading to treatment discontinuation were hypersensitivity reactions (6% of patients)—including anaphylaxis
(3% of patients) and angioedema (1% of patients)—arthralgia (4% of patients), generalized skin reactions
lasting at least 14 days (2% of patients), and injection site reactions (1% of patients)
The most common adverse reactions leading to dosage reduction were arthralgia (14% of patients),
hypersensitivity reactions (9% of patients), injection site reactions (4% of patients), alopecia (3% of
patients), and generalized skin reactions lasting at least 14 days (2% of patients)
The most common adverse reactions leading to temporary drug interruption were arthralgia (13% of
patients), hypersensitivity reactions (13% of patients), anaphylaxis (4% of patients), and injection site
reactions (4% of patients)
Blood Phenylalanine Monitoring and Diet
Obtain blood phenylalanine concentrations every 4 weeks until a maintenance dosage is established
After a maintenance dosage is established, periodically monitor blood phenylalanine concentrations
Counsel patients to monitor dietary protein and phenylalanine intake, and adjust as directed by their
healthcare provider
DRUG INTERACTIONS
Effect of PALYNZIQ on Other PEGylated Products
In a single-dose study of PALYNZIQ in adult patients with PKU, 2 patients receiving concomitant
injections of medroxyprogesterone acetate suspension (a formulation containing PEG 3350) experienced
hypersensitivity reactions, and 1 of the 2 patients also experienced anaphylaxis
The clinical effects of concomitant treatment with different PEGylated products is unknown. Monitor
patients treated with PALYNZIQ and concomitantly with other PEGylated products for hypersensitivity
reactions
USE IN SPECIFIC POPULATIONS
Pregnancy and Lactation
PALYNZIQ may cause fetal harm when administered to a pregnant woman
If PALYNZIQ is administered during pregnancy, or if a patient becomes pregnant while receiving PALYNZIQ
or within 1 month following the last dose of PALYNZIQ, healthcare providers should report PALYNZIQ exposure
by calling 1-866-906-6100
Monitor blood phenylalanine concentrations in breastfeeding women treated with PALYNZIQ
Pediatric Use
The safety and efficacy of PALYNZIQ in pediatric patients have not been established
Geriatric Use
Clinical studies of PALYNZIQ did not include patients aged 65 years and older
You are encouraged to report suspected adverse reactions to BioMarin at 1-866-906-6100
and the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see full Prescribing Information, including Boxed Warning, at PALYNZIQ.com/hcp.
INDICATION
PALYNZIQ™ (pegvaliase-pqpz) Injection is a phenylalanine-metabolizing enzyme indicated to reduce blood
phenylalanine concentrations in adult patients with phenylketonuria (PKU) who have uncontrolled blood
phenylalanine concentrations greater than 600 µmol/L on existing management.
